With the COVID-19 pandemic, effective use of educational technologies has become essential. Many different aspects of technology have been introduced or further expanded, including remote experiential learning or simulations for virtual patient care. At the same time, artificial intelligence enabled faculties to accelerate and advance research and clinical care in the pharmaceutical sciences and clinical pharmacy practice.

Introduction and implementation of any technology-enabled education and training includes many success factors such as technology literacy amongst educators and students. To enhance technology-enabled pharmaceutical education, this digital event will outline good practices and engage participants in identifying a SWOT (Strengths, Weaknesses, Opportunities, and Threats) of technology and AI use in education.

At the end of this session, participants will: 
1.Learn about current and future good practices about the educational technologies used in higher/pharmaceutical education
2.Contribute to the development of a SWOT in using Technology & AI in pharmaceutical education
3.Identify ways to enhance quality of education and academic capacity by utilizing technology and AI in pharmaceutical education

Co-chairs:
- Lilian Azzopardi, Dean Department of Pharmacy, University of Malta, Malta
- Jaime Acosta Gómez, FIP Community Pharmacy Section, FIP Technology Forum co-chair, FIP COVID19 Expert Advisory Group member; Community Pharmacist and pharmacy owner Farmacia Acosta, Spain

Panelists:
-Mia Sivén, Vice-Dean University of Helsinki, Finland
-Francesca Wirth, Senior Lecturer University of Malta, Malta
-Daniel Malone, Pharmacy Course Director Monash University, Australia

Facilitator:
-Aysu Selcuk, FIP AIM Advisory Committee Member, FIP Education and Primary Health Care Policies Specialist, Turkey

This event discusses current evidence for the impact of the pharmaceutical workforce, pharmacy practice and pharmaceutical science.  It discusses and evidence-based approach and identifies challenges and opportunities for generating evidence that will advance the profession.

Aim
To showcase how data and intelligence can be used to provide evidence of impact of pharmaceutical practice, science and education/workforce.

Learning objectives

• Discuss approaches to securing evidence for the impact of the pharmaceutical workforce and pharmaceutical services.
• Discuss strategies and programmes in place to enable timely access to safe, effective and affordable medicines.
• Identify challenges and opportunities for generating evidence of impact.

Moderator:
- Christopher John, FIP Lead for Data and Intelligence, UK

Panellist: 

- Noe Garin Escriva, Hospital Pharmacist, Hospital de la Santa Creu i Sant Pau, Spain
- Harriet Rachel Kagoya, Uganda
- Safa Damiati, Assistant Professor, King Abdulaziz University, Suadi Arabia
- Sherly Meilianti, FIP Data and Intelligence Specialist, Indonesia
- Hilwan Yuda Teruna, Vice President, Indonesian Pharmacists Association, Indonesia

Gastrointestinal health and digestive wellness can be influenced by several lifestyle factors, including diet and stress, and using certain types of medicines. It is important for pharmacists to consider these factors when interacting with patients who present with such symptoms. Different non-prescription medicines are available to treat symptoms related to GI complaints and digestive wellness, rendering pharmacies key access points for trusted advice and access to self-care products which can provide relief and care to affected individuals. This event marks the World Digestive Wellness Day (29 May).

By the end of the session participants should be able to:
• Understand the role of pharmacists in providing advice on digestive wellness
• Understand the relationship between gut wellness and immunity
• Identify practical ways to support better digestive wellness in the community

In order to ensure pharmacists maintain currency and quality in their practice, mandatory continuing professional development (CPD) programmes have been implemented by regulatory authorities as part of the licence renewal requirements for continuing practice. This webinar will provide information on the countries having a mandatory CPD programme, the various types of programmes, the regulations and the overall value and monitoring. In addition, information will be provided on CPD for specialized areas of practice, as part of returning to practice and some new concepts to insure currency and quality.

The attendees will learn:
-the overall importance of a mandated CPD programme from a quality assurance and patient safety perspective ;
-the variations of CPD programmes currently in place in various countries;
-the legislation/regulations in place mandating a CPD programme to maintain currency and enhance competence, quality assurance and patient safety;  
-recertification programs for "specialization" and "return to practice"; and,
-other innovative way to insure quality and currency of pharmacists.

Moderator:
- Brett Simmonds, Chair Pharmacy Board of Australia, Australia

Panelists:
- Carine Wolf-Thal, Chair of the National Council of the French Chamber of Pharmacists, France
- Michael Pead, Chief Executive Pharmacy Council of New Zealand, New Zealand
- Trish Farrelly, Manager Registration and Competence Assurance, Pharmacy Council of New Zealand, New Zealand
- Joe R. Anderson, Assistant Dean for Curricular Affairs and Associate Professor of Pharmacy Practice and Administrative Sciences, The University of New Mexico College of Pharmacy, USA

Constipation is a common symptom pharmacists encounter in daily practice. It is often a self-limiting symptom that can be adequately managed in the community through the use of non-prescription medicines, as well as dietary and lifestyle measures. This event will explore how community pharmacists may support the management of constipation and empower individuals for optimal self-care.

By the end of the session participants should be able to:
• Understand the role of pharmacists in managing constipation in the community
• Understand the influence of fibre, exercise, and fluids in constipation
• Explore the complications of constipation medicines, especially in older adults

Current and future policy: enablers and barriers.

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder that affects people of all ages. Pharmacists can play an important role in symptom management, referral to other healthcare professionals and provision of advice to improve quality of life. This event will provide an overview of the main roles pharmacists can have in supporting people living with IBS, from a community pharmacy perspective.

By the end of the session participants should be able to:
• Discuss the role of community pharmacists around IBS
• Understand the difference in symptoms between abdominal cramping pain and IBS
• Identify red flag symptoms for referral of IBS patients

In many countries, vaccination coverage rates are suboptimal, and vaccination services are largely focused on childhood. Goals to expand vaccination pathways include to have more and more easily accessible vaccination points, and more professionals who can deliver the service to more people and offer evidence-based advice on vaccines. This event will discuss the drivers and barriers to interprofessional understanding, cooperation and task sharing in the area of vaccination in each region, and the regulatory authority granted to different healthcare professionals to prescribe and/or administer vaccines.

Learning objectives:
- Identify drivers and barriers related to the regulatory landscape of vaccination in the region
- Learn about examples of best practices in terms of interprofessional cooperation and task-sharing involving pharmacists in the area of vaccination
- Explore the plans for switching from a pandemic to an endemic response in the region, including the role of pharmacist in vaccination, and in patient care and treatment

The importance of good mental health and wellbeing has gained attention over the last decade due to an increased burden of disability and loss of quality of life associated with mental health conditions. Pharmacists have a role to play in the care and management of mental health illnesses and the stigma associated with them. FIP has developed a new handbook to support pharmacists and their organisations in providing a range of mental health-related services. This handbook — which will be launched at this event — also identifies the knowledge and skills that pharmacists require for the provision of such services, thus offering guidance to academic institutions and CPD providers. This handbook is part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

Learning objectives:  

1. Explore the role of pharmacists in the identification, care and management of mental health illnesses;
2. Identify the challenges and opportunities for pharmacists in addressing mental health illnesses;
3. Identify the relevant knowledge and skills required for the delivery of mental health-related services.

Current and future practice. Policy and professional enablers and barriers

Asthma and chronic obstructive pulmonary disease are two common chronic respiratory diseases that affect hundreds of millions of people worldwide. Pharmacists have an important role to play in their prevention, care and management. FIP has developed a new handbook to support pharmacists and their organisations in providing a range of chronic respiratory diseases-related services. This handbook — which will be launched at this event — also identifies the knowledge and skills that pharmacists require for the provision of such services, thus offering guidance to academic institutions and CPD providers. This handbook is part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

Learning objectives:

1. Explore the role of pharmacists in the prevention, care and management of chronic respiratory diseases and its complications;
2. Identify the challenges and opportunities for pharmacists in addressing chronic respiratory diseases;
3. Identify the relevant knowledge and skills required for the delivery of chronic respiratory diseases-related services.

The World Health Organization estimate that 17.9 million people die from cardiovascular diseases each year, representing 32% of all global deaths. Pharmacists have a role to play in the prevention, care and management of cardiovascular diseases and their complications. FIP has developed a new handbook to support pharmacists and their organisations in providing a range of cardiovascular diseases-related services. This handbook — which will be launched at this event — also identifies the knowledge and skills that pharmacists require for the provision of such services, thus offering guidance to academic institutions and CPD providers. This handbook is part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

Learning objectives:

1. Explore the role of pharmacists in the prevention, care and management of cardiovascular diseases and their complications;
2. Identify the challenges and opportunities for pharmacists in addressing cardiovascular diseases;
3. Identify the relevant knowledge and skills required for the delivery of cardiovascular diseases-related services.

Current and future science. Enablers and barriers to innovation and collaboration across pharmaceutical science.

The fuel behind the advancement of precision medicine is the rapid growth of underlying technologies, from high-throughput sequencing and imaging to machine learning and clinical decision support systems. What are the cutting-edge technologies and fields, and what trends can we expect in the future?

The webinar will cover:

- Ongoing technological developments

- Examples of clinical application of the above technologies in a research context

- Thoughts on future directions of the field, and unaddressed gaps

- Changes to pharmacy education that are needed for future pharmacists to be competent in implementing precision medicine practices effectively

- Gaps and challenges in the field that pharmacists and pharmaceutical scientists could address

Cancer is the second leading cause of death globally, accounting for 9.6 million deaths, according to the World Health Organization. Pharmacists have a role to play in ensuring the prevention, in supporting patients to undergo frequent screening or even collaborate in screening campaigns for certain types of cancer, in managing oncological medication for optimal outcomes, in supporting self-care and the management of symptoms that some treatments might cause and in providing emotional support. FIP has developed a new handbook to support pharmacists and their organisations in providing a range of cancer-related services. This handbook — which will be launched at this event — also identifies the knowledge and skills that pharmacists require for the provision of such services, thus offering guidance to academic institutions and CPD providers. This handbook is part of the FIP Practice Transformation Programme on Non-Communicable Diseases.

 Learning objectives:

1. Explore the role of pharmacists in the prevention, care and management of cancer;
2. Identify the challenges and opportunities for pharmacists in addressing cancer;
3. Identify the relevant knowledge and skills required for the delivery of cancer-related services.

Current and future pharmaceutical education. Enablers and barriers to innovation and high quality education.

Among the greatest bottlenecks for the widespread implementation of precision medicine is the growing costs of the associated technologies. It also brings new challenges for health technology assessment, with cost-utility becoming more difficult to evaluate and predict at finer levels of patient stratification. What are these challenges? How could we address them? How might we go about refining precision medicine strategies to maximize cost utility?

The webinar will cover:

- The current health technology assessment stance on precision medicine applications

- What we know and what we don’t know about the cost-utility of new precision medicine approaches against the standard of care

- How costs may evolve with emerging technologies or trends

- Priorities for future health economics research in this area